| Bioactivity | LSD1-IN-26 (compound 12u) is a potent LSD1 inhibitor, with an IC50 of 25.3 nM. LSD1-IN-26 also inhibits MAO-A (IC50=1234.57 nM) and MAO-B (IC50=3819.27 nM). LSD1-IN-26 significantly induces apoptosis in MGC-803 cells. LSD1-IN-26 can be used for gastric cancer research[1]. |
| Invitro | LSD1-IN-26 (compound 12u) 对 MGC-803、KYSE450 和 HCT-116 细胞表现出高效作用，IC50 值分别为 14.3±1.18、22.8±1.45 和 16.3±2.22 μM，高于 GSK-LSD1 (HY-100546) (IC50 > 64 μM) 和 GSK-2879552 (HY-18632) (IC50 > 64 μM)[1]。LSD1-IN-26 (0-24 μM, 48 h) 诱导 H3K4 Me1/2 和 H3K9 Me2/3 的积累以及 Bcl-2 和 c-IAP1 的减少[1]。LSD1-IN-26 (0-24 μM, 48 h) 诱导细胞凋亡和分化，抑制迁移和细胞干性[1]。 Western Blot Analysis[1] Cell Line: |
| Name | LSD1-IN-26 |
| Formula | C27H25Cl2F2N3O |
| Molar Mass | 516.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ma QS, et al. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment. Eur J Med Chem. 2023 May 5;251:115228. |